Relapsing-remitting multiple sclerosis: Metabolic abnormality in nonenhancing lesions and normal-appearing white matter at MR imaging: Initial experience

Radiology

Volumn 234, Issue 1, 2005, Pages 211-217

  He, Juan ^a   Inglese, Matilde ^a   Li, Belinda S Y ^a   Babb, James S ^a   Grossman, Robert I ^a   Gonen, Oded ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; CREATINE; N ACETYLASPARTIC ACID;

ADULT; BRAIN INJURY; BRAIN METABOLISM; CONTROLLED STUDY; FEMALE; GLIOSIS; HUMAN; HUMAN EXPERIMENT; INFLAMMATION; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE ANALYSIS; REMYELINIZATION; REVIEW; THREE DIMENSIONAL IMAGING; WHITE MATTER;

ADULT; ASPARTIC ACID; BRAIN; CASE-CONTROL STUDIES; CHOLINE; CREATINE; FEMALE; HUMANS; IMAGING, THREE-DIMENSIONAL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 10644295634     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2341031895     Document Type: Review

References (46)

1. Miller DH, Grossman RI, Reingold SC, McFarland HF. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 1998; 121:3-24.
2. Arnold DL, Matthews PM. MRI in the diagnosis and management of multiple sclerosis. Neurology 2002; 58(8 suppl 4): S23-S31.
3. Filippi M. Linking structural, metabolic and functional changes in multiple sclerosis. Eur J Neurol 2001; 8:291-297.
4. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47:707-717.
5. Hiehle JF Jr, Grossman RI, Ramer KN, Gonzalez-Scarano F, Cohen JA. Magnetization transfer effects in MR-detected multiple sclerosis lesions: comparison with gadolinium-enhanced spin-echo images and nonenhanced T1-weighted images. AJNR Am J Neuroradiol 1995; 16:69-77.
6. van Walderveen MA, Kamphorst W, Scheltens P, et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 1998; 50:1282-1288.
7. van Waesberghe JH, van Walderveen MA, Castelijns JA, et al. Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. AJNR Am J Neuroradiol 1998; 19:675-683.
8. van Walderveen MA, Barkhof F, Pouwels PJ, van Schijndel RA, Polman CH, Castelijns JA. Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy. Ann Neurol 1999; 46:79-87.
9. Brex PA, Parker GJM, Leary SM, et al. Lesion heterogeneity in multiple sclerosis: a study of the relations between appearances on T1 weighted images, T1 relaxation times, and metabolite concentrations. J Neurol Neurosurg Psychiatry 2000; 68:627-632.
10. Bitsch A, Kuhlmann T, Stadelmann C, Lassmann H, Lucchinetti C, Bruck W. A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions. Ann Neurol 2001; 49:793-796.
11. Li BS, Regal J, Soher BJ, Mannon LJ, Grossman RI, Gonen O. Brain metabolite profiles of T1-hypointense lesions in relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol 2003; 24:68-74.
12. Bruck W, Bitsch A, Kolenda H, Bruck Y, Stiefel M, Lassmann H. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 1997; 42:783-793.
13. Arnold DL, Matthews PM, Francis G, Antel J. Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease. Magn Reson Med 1990; 14:154-159.
14. Gonen O, Murdoch JB, Stoyanova R, Goelman G. 3D multivoxel proton spectroscopy of human brain using a hybrid of 8th-order Hadamard encoding with 2D chemical shift imaging. Magn Reson Med 1998; 39:34-40.
15. Marion D, Ikura M, Bax A. Improved solvent suppression in one- and two-dimensional NMR spectra by convolution of time domain data. J Magn Reson 1989; 84:425-430.
16. Campbell ID, Dobson CM, Williams RJP, Xavier ZV. Resolution enhancement of protein PMR spectra using the difference between a broadened and normal spectrum. J Magn Reson 1973; 11:172-181.
17. Vigneron DB, Nelson SJ, Murphy-Boesch J, et al. Chemical shift imaging of human brain: axial, sagittal and coronal 31P metabolite images. Radiology 1990; 177:643-649.
18. Barkhof F, Karas GB, van Walderveen MA. T1 hypointensities and axonal loss. Neuroimaging Clin N Am 2000; 10:739-752, ix.
19. Soher BJ, Young K, Govindaraju V, Maudsley AA. Automated spectral analysis III: application to in vivo proton MR spectroscopy and spectroscopic imaging. Magn Reson Med 1998; 40:822-831.
20. Soher BJ, van Zijl PC, Duyn JH, Barker PB. Quantitative proton MR spectroscopic imaging of the human brain. Magn Reson Med 1996; 35:356-363.
21. Hoult DI, Richards RE. The signal-to-noise ratio of the nuclear magnetic resonance experiment. J Magn Reson 1976; 24:71-85.
22. Henriksen O. In vivo quantitation of metabolite concentrations in the brain by means of proton MRS. NMR Biomed 1995; 8:139-148.
23. Kreis R, Ernst T, Ross BD. Absolute quantitation of water and metabolites in the human brain. II. Metabolite concentrations. J Magn Reson B 1993; 102:9-19.
24. Christiansen P, Toft P, Larsson HB, Stubgaard M, Henriksen O. The concentration of N-acetyl aspartate, creatine + phosphocreatine, and choline in different parts of the brain in adulthood and senium. Magn Reson Imaging 1993; 11:799-806.
25. Ernst RR, Bodenhausen G, Wokaun A. Principles of nuclear magnetic resonance in one and two dimensions. Oxford, England: Clarendon Press, 1987; 152.
26. Helms G. Volume correction for edema in single-volume proton MR spectroscopy of contrast-enhancing multiple sclerosis lesions. Magn Reson Med 2001; 46:256-263.
27. Davie CA, Hawkins CP, Barker GJ, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994; 117:49-58.
28. Simmons ML, Frondoza CG, Coyle JT. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 1991; 45:37-45.
29. De Stefano N, Matthews PM, Fu LQ, et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis: results of a longitudinal magnetic resonance spectroscopy study. Brain 1998; 121:1469-1477.
30. Urenjak J, Williams SR, Gadian DG, Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 1993; 13:981-989.
31. Arnold DL, Matthews PM, Francis GS, O'Connor J, Antel JP. Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann Neurol 1992; 31:235-241.
32. Husted CA, Goodin DS, Hugg JW, et al. Biochemical alterations in multiple sclerosis lesions and normal-appearing white matter detected by in vivo 31P and 1H spectroscopic imaging. Ann Neurol 1994; 36:157-165.
33. Uhlenbrock D, Sehlen S. The value of T1-weighted images in the differentiation between MS, white matter lesions, and subcortical arteriosclerotic encephalopathy (SAE). Neuroradiology 1989; 31:203-212.
34. van Waesberghe JH, Kamphorst W, De Groot CJ, et al. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol 1999; 46:747-754.
35. Truyen L, van Waesberghe JH, van Walderveen MA, et al. Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology 1996; 47:1469-1476.
36. van Walderveen MA, Barkhof F, Hommes OR, et al. Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin-echo images. Neurology 1995; 45:1684-1690.
37. Werring DJ, Clark CA, Barker GJ, Thompson AJ, Miller DH. Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis. Neurology 1999; 52:1626-1632.
38. Koudriavtseva T, Thompson AJ, Fiorelli M, et al. Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1997; 62:285-287.
39. Simon JH, Lull J, Jacobs LD, et al. A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Neurology 2000; 55:185-192.
40. Rovira A, Alonso J, Cucurella G, et al. Evolution of multiple sclerosis lesions on serial contrast-enhanced T1-weighted and magnetization-transfer MR images. AJNR Am J Neuroradiol 1999; 20:1939-1945.
41. Mader I, Roser W, Kappos L, et al. Serial proton MR spectroscopy of contrast-enhancing multiple sclerosis plaques: absolute metabolic values over 2 years during a clinical pharmacological study. AJNR Am J Neuroradiol 2000; 21:1220-1227.
42. Arnold DL, de Stefano N, Matthews PM, Trapp BD. N-acetylaspartate: usefulness as an indicator of viable neuronal tissue. Ann Neurol 2001; 50:823-825.
43. Allen IV, McKeown SR. A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis. J Neurol Sci 1979; 41:81-91.
44. De Stefano N, Narayanan S, Pelletier D, Francis GS, Antel JP, Arnold DL. Evidence of early axonal damage in patients with multiple sclerosis (letter). Neurology 1999; 52:378.
45. Sarchielli P, Presciutti O, Pelliccioli GP, et al. Absolute quantification of brain metabolites by proton magnetic resonance spectroscopy in normal-appearing white matter of multiple sclerosis patients. Brain 1999; 122:513-521.
46. Inglese M, Li BS, Rusinek H, Babb JS, Grossman RI, Gonen O. Diffusely elevated cerebral choline and creatine in relapsing-remitting multiple sclerosis. Magn Reson Med 2003; 50:190-195.